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Abstract
Mammary gland tissue changes appearance and functionality in different sequential 
steps. The tissue of virgin, pregnant, or lactating mammary glands changes controlled 
by finely regulated physiological processes. A fourth stage (involution), triggered upon 
weaning, involves remodeling, and the gland regresses to resemble a prepregnant stage. 
This highly complex process characterized by a high degree of epithelial cell death and 
tissue remodeling can be divided into phases, which can be independent of each other. 
The present article describes a variety of signaling pathway components, transcription 
factors, and mRNA stabilization proteins that play a role in the regulation of cell fate 
during the involution process. These molecular actors are finely related in health to trig-
ger the delicate mechanism that govern involution after weaning, leaving the gland in 
a latent stage until needed again. Importantly, it has been shown that this process may 
contribute to cancer development in the years following childbirth, mainly because of the 
involvement of inflammatory and remodeling factors.
Keywords: mammary gland involution, transcription factors, inflammatory cytokines, 
STATs, cell death, TNF-α, mRNA stability, breast cancer
1. Introduction
Upon weaning, the mammary gland recovers a morphology similar to its prepregnant state 
through an intricate process known as postlactational involution. During this phase, a high 
proportion of epithelial cells die, the basal membrane is partially digested, and the adipose tis-
sue reoccupies the space left by the regressed alveoli. In the mouse, mammary gland involution 
has been described as a two-step process according to its reversibility [1]. The first reversible 
phase is induced by local factors and lasts approximately 48 h during which it can be reversed 
through resuckling. At this stage, proapoptotic factors are upregulated, while survival factors 
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are reduced. This reversible phase is followed after 72 h by a nonreversible phase where wide-
spread apoptosis and tissue remodeling takes place. This later phase requires systemic factors 
and local proteases such as MMP-3/Stromelysin-1 and MMP11/Stromelysin-3, MMP2/Gelatinase 
A, ICE (interleukin-1 beta converting enzyme), and Urokinase-type plasminogen activator [2].
In 1997, Li et al. [3] defined the role of local factors as compared with systemic hormones 
during the first and second stages of involution. When milk release was disrupted in the pres-
ence of systemic lactogenic hormones, they demonstrated that local signals were sufficient to 
induce alveolar cell death. These authors demonstrated that a variety of procedures success-
fully triggered mammary involution, although none of them prevented the presence of cir-
culating lactogenic hormones. For example, sealing of the teats, mammary gland transplants 
unable to release milk due to the absence of a teat connection or inactivation of the oxytocin 
gene efficiently induced mammary cell death. On the other hand, in these scenarios, systemic 
hormones were able to preserve lobular-alveolar structure, although they did not prevent 
apoptosis. This chapter reviews the discovery of the local factors involved in the process of 
involution as well as the finding of the mechanisms involved in their ability to induce cell 
death shortly after weaning. In addition, the generation of a pro-oncogenic microenviron-
ment during mammary involution, which is able to facilitate breast cancer progression, is 
also discussed.
2. Involvement of STAT3 signaling
The studies referred above found that cell death correlated with the induction of proapop-
totic genes as bax, decreased expression of milk proteins, dephosphorylation of STAT5a and 
5b (main transcription factors that mediate prolactin triggered signaling), and activation of 
STAT3. Signal transducer and activator of transcription (STATs) are a family of latent tran-
scription factors, which are activated in response to a variety of cytokines and growth fac-
tors. This family of signaling molecules has been implicated in cell growth, differentiation, 
survival, and apoptosis. STAT3 and STAT5 have reciprocal patterns of activation throughout 
a mammary developmental cycle, suggesting that STAT5 may be a survival factor and STAT3 
a death factor for differentiated mammary epithelium. Chapman et al. [4], using the lox/Cre 
recombination system, showed a decrease in epithelial apoptosis and a dramatic delay of the 
involution process upon forced weaning in conditional KO mice, in which STAT3 was spe-
cifically deleted in the lactating mammary gland. In addition, early activation of STAT1 and 
induction of p53 and p21 expression was observed, which suggested a potential compensa-
tory mechanism for induction of eventual involution in the STAT3 null mammary glands. 
These results demonstrated the importance of STAT factors in signaling the initiation of phys-
iological apoptosis in vivo and highlighted the utility of the lox/Cre system for addressing the 
function of genes with an embryonic lethal phenotype, specifically in the mammary gland.
STAT3 is the most ubiquitous of the members of this family of proteins, is activated by many 
different cytokines and growth factors, and plays many roles in different physiological pro-
cesses. In addition, this protein is, the first STAT family member found to be constitutively 
activated in a variety of neoplastic tissues. It was determined that STAT3 modulates the 
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expression of various target genes involved in cell-cycle regulation, angiogenesis, and apop-
tosis inhibition. Because of this, silencing or inhibiting STAT3 reduces tumor cell proliferation 
and survival in both animal and human studies. However, in the involuting mammary gland, 
STAT3 signaling induces cell death [5].
By 2003, it had been shown that STAT3 is the main factor involved in the initiation of apopto-
sis of mammary cells after weaning, but the mechanism of its activation remained unclear. In 
2002, based on the hypothesis that IL-6 is the activating cytokine for STAT3, Hennighausen’s 
group showed that expression of IL-6 increases during early involution together with STAT3 
and p44/42 MAPK activation. Besides, it was shown that IL-6 treatment activated STAT3 in the 
mammary gland of virgin and lactating mice. In addition, IL-6-, STAT3-, and Bax-null mice 
showed similar mammary phenotypes, that is a significant delay in postlactational involu-
tion. Nevertheless, it was demonstrated that STAT3 activation during involution was inde-
pendent of the IL-6 levels in the mammary after weaning. In contrast, the increase of p44/42 
MAPK (ERK1/2) phosphorylation at the onset of involution was dependent on the presence 
of this cytokine. This suggested that either IL-6 does not induce STAT3 in vivo or its absence is 
compensated for by other cytokines, such as leukemia-inhibitory factor (LIF) [6].
By that time, there was no evidence in the literature reporting LIF expression and/or activities 
in the normal mammary gland tissue. Therefore, LIF expression profile was analyzed during 
the successive stages of mammary gland development, function, and involution. The results 
demonstrated that LIF is expressed in the mammary gland at low levels in postpubertal, adult 
virgin, and pregnant mice. But, expression of this protein almost disappear during lactation to 
then show a significant increase a few hours after weaning, maintaining these high levels dur-
ing the following days. We demonstrated that LIF expression in the gland is induced by milk 
stasis and not by the decrease of circulating lactogenic hormones after weaning. In addition, 
implantation of LIF containing pellets in lactating glands resulted in a significant increase 
of STAT3 phosphorylation and epithelium apoptosis. We then concluded that LIF-regulated 
expression in the mouse mammary gland may play a relevant role during the first stage of 
mammary gland involution and that LIF-induced mammary epithelium apoptosis could be 
mediated, at least partially, by STAT3 activation [7].
Shortly after our paper was published, Christine Watson’s lab also demonstrated that LIF is 
the physiological activator of STAT3, as they report that pSTAT3 is absent and C/EBPdelta (a 
well-known STAT3 target) is not upregulated in involuting transplanted mammary glands 
of LIF double knock-out (LIF(−/−) mice). Similarly to what was observed in the STAT3-null 
glands, LIF(−/−) mammary glands exhibit delayed involution, reduced apoptosis, and ele-
vated levels of p53 [8].
STAT3 activation and LIF expression have not been observed only in the involuting mammary 
gland. It was determined that autocrine/paracrine LIF present in conditioned medium from 
primary cultures of mouse mammary tumors was also able to induce activation of that tran-
scription factor and to increase cell survival in mammary tumor cell lines. However, although 
LIF blocking antibody prevented STAT3 phosphorylation, inhibition of STAT3 increased cell 
survival. These results indicated that LIF is overexpressed in mouse mammary tumors, where 
it acts as the main STAT3 activator. Nevertheless, the data also suggested that the positive 
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LIF effect on tumor cell survival was not dependent on STAT3 activation, which seemed to 
inhibit tumor cell viability as it does in involuting mammary epithelium [9]. Kritikou et al. 
showed that pERK1/2 is significantly reduced in LIF(−/−) glands during pregnancy [8], sug-
gesting that at this stage, LIF mediates its effects through pERK1/2. Therefore, it is possible 
that LIF proliferative effects on mammary tumors depend on ERK ½ activation. In addition, 
although it has been reported that STAT3 acts a potent oncogene in different tumor types, 
it was also demonstrated that the biological role of this factor is modulated by the stage of 
tumor progression [10]. Similarly, it can be proposed that in well-to-moderately differentiated 
mammary tumors, STAT3 activation induces cell death as observed in nontumorigenic mam-
mary cells after lactation. This activity might be altered in more aggressive or less differenti-
ated tumors, as it has been shown that STAT3 constitutive activation is very common in basal 
breast cancer [11], which have worse prognosis than luminal tumors. However, our results 
imply that in the development of therapeutic strategies for blocking STAT3 in breast cancer 
cells, the strong dependence on the cellular context that this factor activity displays should be 
taken into account.
Mechanical stress is a relevant factor to induce adaptive responses in multiple cell types [12–16]. 
Importantly, the signaling pathways triggered by this stimulus in those different examples also 
play a relevant role during mammary gland involution. Therefore, it was proposed that upon 
weaning, milk accumulation may cause cell stretching that, in turn, would induce the initia-
tion of the molecular cascades that lead to the remodeling process of the lactating gland. To 
address this issue, we designed a new practical device that allowed us to evaluate the effects of 
radial stretching on the HC11 nontumorigenic mammary epithelial cell line cultured on flex-
ible silicone membranes. The results showed that, as previously observed in other cell types, 
mechanical stress induced ERK1/2 phosphorylation and c-Fos expression induction, as well as 
LIF secretion, STAT3 activation, and AKT phosphorylation inhibition. Therefore, mechanical 
strain is able to induce weaning-associated events in cultured mammary epithelial cells [17].
STAT3 is essential, but not sufficient for the onset of apoptosis during mammary involution, 
as expression of a constitutively active Akt, a downstream effector of the phosphoinositide-
3-OH kinase (PI3K) pathway, provides an overriding survival signal after lactation [18]. 
However, AKT downregulation depends on STAT3 activation, since PI(3)K regulatory sub-
units p55α and p50α (each of them, when overexpressed, reduces levels of activated AKT) 
are induced by that transcription factor during mammary involution. In fact, it has been 
shown that STAT3 binds directly to the promoters of p55α and p50α subunits in vivo and in 
STAT3 KO mice, upregulation of p55α and p50α is abrogated, levels of activated AKT are 
sustained, and apoptosis is prevented [19]. In addition, it was shown that deletion of both 
p55α and p50α subunits reduced cell death as well as expression and activity of cathepsin L 
during mammary involution. This protease participates in lysosomal-mediated programmed 
cell death (LM-PCD), which is upregulated during normal involution by activated STAT3. 
Furthermore, involution is delayed in cathepsin L-deficient mice, suggesting that the p55α/
p50α subunits mediate cell death in part by elevating the level of cathepsin L. Surprisingly, 
it was found that during involution, p55α/p50α localize to the nucleus where they bind to 
chromatin and regulate transcription of a subset of inflammatory/acute phase genes that are 
also STAT3 targets. Therefore, these findings revealed that postlactational regression of the 
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mammary gland is accomplished through a nonclassical, lysosomal-mediated pathway of 
cell death, in which PI3K regulatory subunits participate as main regulators [20]. In fact, 
it has been demonstrated that cell death of mammary epithelium after weaning does not 
depend on the activation of executioner caspases 3, 6, and 7, although it requires STAT3 for 
cathepsin B and L induction as well as for the downregulation of their endogenous inhibitor 
Spi2A [21].
Global gene expression changes during involution have been profiled by microarray anal-
ysis, which allowed characterization of clusters of genes with distinct expression profiles 
during the first 4 days of involution. Such expression profiling led to the observation that 
one of the most strikingly upregulated genes in the absence of STAT3 is the serpin Spi2a. 
Interestingly, during mammary involution, STAT3 not only regulates LM-PCD by inhibiting 
serpin Spi2a, inducing the expression of cathepsins B and L, and the regulatory subunits 
p55α/p50α, but also by the uptake of secreted MFGs that lead to the formation and fusion 
of large lysosomal-like vacuoles, which are toxic to epithelial cells. Upon re-entry, the MFG 
(mammary fat globules) triglycerides are metabolized to free fatty acids, including oleic acid, 
that can distort membranes and result in leakage of cathepsins from lysosomes. Therefore, 
STAT3 promotes a phenotypic switch from secretion to phagocytosis of MFGs, the latter 
function delivering triglyceride to vacuoles with the ensuing consequences of LMP and cell 
death [22].
3. NF-κB signaling
It is clear that there are multiple mechanisms of regulation in early involution that synergise 
to ensure efficient induction of cell death, phagocytosis, suppression of inflammation, and 
remodeling of the architecture of the gland. Clarkson and Watson identified clusters of genes 
that are transcriptional targets of either NF-κB or STAT3, or indeed both, during early invo-
lution [23]. For example, among the NFκB targets, the TNF superfamily of death receptor 
(DR) ligands have been detected. These proteins induce apoptosis through binding to their 
receptor, which recruits caspase 8 (via FADD) and activates executioner caspases, finally lead-
ing to cell death [24]. Specifically, Tnf, Tnfsf4, Tnfsf6, Tnfsf7, Tnfsf10, and Tnfsf12 are induced 
transiently at 12 h after weaning, and the proteins Fas ligand, TNF-α, TWEAK, and TRAIL 
are able to activate extrinsic apoptosis through their cognate receptors Fas, TNFR-1, TNFR-
2, DR3, and DR4. The genes for the first two of these receptors (Fas and Tnfrsf1a) were also 
induced, and maximally coexpressed, within 24 h of weaning. NF-κB activity also correlated 
with the rapid activation of these TNF superfamily ligands [25].
Particularly, about TNF-α, our results have shown that this factor, through TNF-α receptor-2 
(TNFR2) binding induces LIF expression mediated by ERK1/2 activation in nontumorigenic 
mouse mammary epithelial cells. In addition, the AP-1 has been implicated in this signaling 
cascade, since blocking the activity of this transcription factor resulted in a significant reduc-
tion of TNF-α induced LIF expression. Therefore, TNF-α may contribute to mammary gland 
involution by, among other activities, eliciting LIF expression through ERK1/2 and AP1 acti-
vation [26].
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The NF-κB family of transcription factors primarily plays anti-apoptotic roles. DNA binding 
activity of this transcription factor is markedly upregulated within 3 h of forced involution 
and is suggested to promote survival of a subpopulation of mammary epithelial cells [25]. 
This hypothesis is consistent with the paradigm of NF-κB–mediated suppression of TNF-α 
cytotoxicity in TNF-α–responsive cells. NF-κB activity is mediated by a multiprotein signaling 
complex called the IκB kinase (IKK), which consists of two catalytic subunits: IKK1/α, IKK2/β 
and a regulatory subunit, NEMO (NF-kappa-B essential modulator). Activation of this com-
plex leads to phosphorylation of the IκB proteins; phospho-IκB is rapidly ubiquitinated and 
degraded via the 26S-proteasome releasing NF-κB and unmasking its nuclear localization 
signal, allowing its activity as transcription regulator of many target genes [27]. NF-κB then 
inhibits the death signal by trans-activating genes that promote resistance to apoptosis. The 
effect of this negative feedback mediated by NF-κB is the modulation of apoptosis in response 
to the TNF-α death signal. However, deletion of the gene encoding IKK2 resulted in delayed 
apoptosis and remodeling, as well as blockade of caspase 3 activation in the postlactational 
mammary gland. This failure to induce cell death was associated with reduced expression 
of TNF and its receptor TNFR1, which are known NF-κB targets. In addition, the observed 
high levels of active AKT together with downregulation of TWEAK, another DR ligand, also 
contributed to retard the involution process in these genetically engineered mice [28]. These 
results suggest that NF-κB may provide either proapoptotic or antiapoptotic signals during 
involution, depending on the timing and cellular context in which this transcription factor is 
activated.
4. Gene expression regulation at the level of mRNA stability
It has been demonstrated that the stability of many messenger RNAs (mRNAs) encoding onco-
proteins, chemokines, cytokines, and other inflammatory mediators is controlled by AU-rich 
elements (AREs), sequences located within the 3’-UTR of many transcripts [29, 30]. ARE-
directed control of mRNA decay is mediated, in part, through interactions with specific ARE-
binding proteins (AUBPs). One such protein is tristetraprolin (TTP), which accelerates the 
decay of targeted transcripts [31]. During inflammation, TTP plays a relevant role destabilizing 
different mRNAs, participating in glucocorticoid-mediated anti-inflammatory activity [32–34] 
and inhibiting NF-κB signaling [35]. The relevance of TTP as a negative regulator of these 
processes has been demonstrated by the severe chronic inflammation displayed by multiple 
tissues in TTP-KO mice, which was mostly due to the dramatic increase of TNF-α levels [32].
Several reports indicate that TTP participates in the inhibition of tumor progression. It 
has been shown that TTP mRNA levels are significantly decreased in many tumor types, 
including breast cancer [36]. We have also reported that TTP expression is lower in all 
breast cancer types compared with normal mammary tissue, and high levels of this pro-
tein negatively correlate with cancer cell aggressiveness. Interestingly, we have also 
determined that in the mouse mammary gland, expression of this protein reaches the 
highest level during lactation, and can be induced in culture by treatment with lactogenic 
hormones [37].
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These studies reveal a new potential biological role for this tumor suppressor protein in mam-
mary epithelium, since TTP might protect the tissue from inflammatory and/or remodeling 
activities that would trigger involution of the gland. Interestingly, our unpublished results 
show that by reducing TTP expression in the differentiated mammary epithelium, cell death 
is induced in the midst of lactation without requirement of additional stimuli. Then, TTP is 
not (or at least not only) a mechanism of surveillance, which prevents an eventual increase of 
inflammatory factors that might lead lactation to a halt, but it actually functions as a survival 
factor in the mammary epithelium, since reducing its levels is enough to induce cell death and 
involution of this tissue.
5. Mammary involution and cancer
Breast cancer is the most frequent malignancy diagnosed in association with pregnancy 
[38–40]. In addition, different studies have demonstrated an increase in breast cancer risk in 
the years immediately following giving birth [41–43]. Importantly, not only a rise in breast 
cancer incidence during the postpartum years has been observed, but also a higher risk for 
poor outcomes in women diagnosed during that timeframe [44]. However, it has been well 
established that pregnancy provides lifetime protection for women who are under 35 years 
at first birth [45–47]. Therefore, pregnancy would exert two opposite effects on breast cancer 
development: induces protection, which is associated with the differentiation of mammary 
epithelium, and increases risk, through alteration of tissue microenvironment.
Postpartum breast cancers have been referred to as type II Pregnancy-Associated Breast 
Cancer (PABC) to distinguish these cancers from those diagnosed during pregnancy [45]. A 
physiological window unique to type II PABC is mammary gland involution and, in an effort 
to distinguish why type II PABC patients have worse prognoses, the normal postpartum 
breast microenvironment has been investigated for potential tumor-enhancing attributes. 
These studies reveal that postpartum involution utilizes wound-healing programs for gland 
remodeling, including increases in matrix metalloproteinase activity, release of bioactive 
fragments of extracellular matrix (ECM) termed matricryptins, accumulation of fibrillar col-
lagen, and influx of immune cells, which also generates tumor-promotional microenviron-
ments [48–51]. In vivo experiments showed that tumors from xenografts of breast cancer cells 
exposed to the postpartum involution microenvironment have increased growth, invasion, 
and metastasis compared to those growing in nulliparous hosts. In addition, these implants 
showed augmented fibrillar collagen accumulation and high cyclooxygenase-2 (COX-2) 
expression [52]. Coincidently, in the postlactating mammary gland, inhibition of COX-2 
reduced the collagen fibrillogenesis, as well as tumor development and cancer cell invasive-
ness [53]. Therefore, it has been proposed that women at high risk for postpartum breast 
cancer might benefit from treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) 
during postpartum, which would reduce COX-2 expression and its consequences on the 
behavior of breast initiated cells.
Without doubt, immune response plays a primordial role in mouse mammary involution, 
since molecular profiling of that phase is consistent with acute phase, innate and adaptive 
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immune responses [51–54]. Interestingly, after weaning, mammary epithelial cells them-
selves express transcripts traditionally associated with immune cells [55, 56] and acquire 
phagocytic capability [57]. Therefore, it has not been possible to completely determine 
which cell types and in what part are responsible for the observed immune-like gene sig-
natures. Particularly, there is not much data about the participation of adaptive immune 
cells, but innate immune cell populations have been partially characterized. Specifically, 
it has been observed that granulocyte infiltration in the mouse gland on the first day of 
involution suggest the involvement of this cell type in early involution [58]. In addition, 
resident macrophages seem to be required for this phase, while infiltrating macrophages 
are important during the remodeling stage [52]. It was observed that on this last phase, 
macrophages express low iNOS, high arginase-1, and the mannose receptor, which is con-
sistent with alternative activation or M2 polarization of these cells [59]. Importantly, this 
phenotype correlated with breast tumor promotion in patients [60] and murine mammary 
tumor progression [61].
The earlier mentioned STAT3 and NF-κB signaling pathways, as well as others involving 
transforming growth factor beta (TGF-β) and the retinoid acid receptors (RARs)/retinoid 
X receptors (RXRs), participate in mammary gland involution as well as in breast cancer 
development. After weaning, target genes of RARα/p300 and RelA/p65, which belong to 
the NF-κB protein family, are induced, and high activity of the proteins coded by these 
genes, e.g., MMP9, Capn1, and Capn2, has been detected in breast cancer cells. Calpains 
belong to a family of calcium-dependent intracellular cysteine proteases involved in a wide 
variety of physiological and pathological processes. These proteases are heterodimers, 
consisting of a small regulatory subunit, encoded by CAPN4 gene, common for both mem-
bers, and a large catalytic subunit encoded by either CAPN1 or CAPN2. During  mammary 
gland involution and cancer progression, these proteins are relevant for  modifying the 
extracellular matrix, allowing tissue remodeling and/or cell invasion. In addition, calpains 
also cleave intracellular proteins located in the cell membrane, lysosomes, mitochondria, 
and nuclei, favoring cell death during involution and cell anchoring loss during tumor 
 progression [62].
6. Conclusion
As in other physiological processes, the use of conditional knockout mice and the appli-
cation of high-throughput techniques have been very useful to understand that normal 
postlactation mammary gland involution relays on the fine-tune coordination of multiple 
signaling pathways. Although involution is a physiologically normal, developmentally 
orchestrated tissue-remodeling process, it shares striking similarities with pathologically 
induced wound-healing and tumor-promotional microenvironments. This highlights the 
relevance of further investigating this process, since it may yield novel therapeutic tar-
gets or prognostic markers for breast cancer. Importantly, studying this particular phase 
of mammary gland biology may help us to pinpoint subtle changes in a pro-oncogenic 
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environment that determines the derailment from normal physiological to pathological 
tissue behavior.
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